China relaxes import regulations to improve access and availability of affordable medicines3 Sep 2019
The potential for generics to support the healthcare needs of China is significant.
In a welcome step and a move that will potentially benefit millions of Chinese citizens, the Govt of the Peoples Republic of China has announced incremental changes to its erstwhile import and regulatory policy that will allow the easier influx of affordable medicines from overseas.
China's structural reform to its local healthcare system furthers its resolve to progressively drive down drug prices, speed up the approval of new medicines so that they can reach the market quickly, paving the way for greater imports of high-quality medicines.
Welcoming the development as positive and much awaited by Indian and global generic manufacturers, Dr Gurpreet Sandhu, President, Council for Healthcare and Pharma (CHP) said: " We hope the initial reforms to open up the Chinese market by 1 December 2019 for generics in small batches will be further deepened to allow for larger imports, as reforms succeed. I believe, as a result, the Chinese population will benefit through greater access and improved availability of a larger basket of essential and improved medicines, at competitive costs, effectively lowering the cost of medical care in China."
There has been a positive response from patients to China cutting back import tariffs on 28 drugs including the much-required anti-cancer drugs from India, which are in great demand due to their lower prices as compared to imports from the West. China is among the most populous countries in the world with an ageing population and its need for medicine is therefore significant and growing. The potential for generics to support the healthcare needs of China is therefore huge.
There are many complementarities that can be unleashed by the Indian Pharmaceutical industry which is today at a high level of maturity and widely regarded for its technical prowess. India's production costs too are approximately 33% lower than in the West (US) and Indian pharmaceuticals account for nearly 20% of global generic exports by volume. India can thus become a stable and reliable source of supply of medicines to China, which is importantly ranked as the second largest pharmaceutical market in the world.
In addition to its significant capacity, India is among the largest importer of bulk drugs from China, which are then converted into intermediaries and finished dosage forms for export to foreign markets. A few Indian companies have hitherto had joint ventures with their Chinese counterparts, which are now being revived. Further investment is also being made to better service the Chinese market and for export from China.
Recent ventures announced by prominent generic companies in China include the pact between Sun Pharma and CMS, Aurobindo Pharma and Luoxin, Cipla and Jiangsu Acebright besides the introduction of a strategic pipeline of 70 products from Dr Reddy's Laboratories and Cancer drugs by NATCO Pharma. The recently announced merger between US majors Mylan and Upjohn also has significant plans to scale up its combined presence in China.
Winners of the 16th Pharma Awards
11 Nov 2019
Companies and individuals from across the whole pharma supply chain recognised for their excellence and commitment.Read more
‘FDA should withdraw ANDAs’ says expert
21 Oct 2019
CPhI Worldwide's Annual Report suggests repeat offenders of regulatory infringements should be barred from importing into the US.Read more
Sanofi opens its first digitally-enabled, continuous manufacturing facility
15 Oct 2019
One of the first digital manufacturing facilities in the world to use continuous, intensified biologics production technology.Read more
EC approves its first plant-derived cannabis-based medicine
24 Sep 2019
Epidyolex (cannabidiol) approved for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.Read more
Integrating glucose sensing and insulin delivery technologies
18 Sep 2019
Collaboration aims to provide a connected device experience for millions of people living with diabetes using insulin.Read more
Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market
9 Sep 2019
Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.Read more
Exciting new vaccine targets killer disease TB
28 Aug 2019
Australian researchers produce early-stage vaccine which is inhaled into the lungs.Read more
Switzerland overtakes Germany as Europe’s biggest drug delivery innovator
16 Aug 2019
Pipeline of new drugs has helped drive increased innovation in packaging and drug delivery devices.Read more
How real-world data can revolutionise drug development
9 Aug 2019
Utilising the current data environment and its data pools for the benefit of advancing research.Read more
Colorcon to incorporate TruTag's edible 'optical barcodes' in tablet film coatings
6 Aug 2019
The benefits of this innovation include the ability to instantly and unequivocally authenticate products when suspect events.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation